An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Zogenix, Inc. (Nasdaq - ZGNX), Social Capital Suvretta Holdings Corp. III (Nasdaq - DNAC), Viveon Health Acquisition Corp. (NYSE American - VHAQ)
BALA CYNWYD, Pa., Jan. 26, 2022 /PRNewswire/ -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or financial obligation to you.
Zogenix, Inc. (Nasdaq: ZGNX)
Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for $26.00 in cash, plus a $2.00 contingent value right (CVR) potential cash payment for each share of Zogenix stock. The investigation concerns whether the Zogenix Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether UCB is paying too little for the Company.
Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC)
Under the terms of the agreement, SCS, a special purpose acquisition company, will combine with ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, and result in ProKidney becoming a publicly-listed company. Under the terms of the agreement, SCS shareholders will retain ownership of only 9% of the combined company. The investigation concerns whether the SCS Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.
Viveon Health Acquisition Corp. (NYSE American: VHAQ)
Under the terms of the agreement, Viveon Health, a special purpose acquisition company, will combine with Suneva Medical, Inc. ("Suneva"), a medical technology company in aesthetic treatments, and result in Suneva becoming a publicly-listed company. Under the terms of the agreement, Viveon Health shareholders will retain ownership of only 39.3% of the combined company. The investigation concerns whether the Viveon Health Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. Attorney advertising. Prior results do not guarantee a similar outcome.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
View original content: